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The discovery of a second estrogen receptor (ER), designated ERβ (NR3A2), has redefined our knowledge
about the mechanisms underlying cellular signaling by estrogens and has broad implications for our
understanding of regulation of estrogen-responsive tissues. Highly variable and even contrasting effects of
estrogens in different tissues seem to be at least partially explained by different estrogen signaling pathways,
involving ERα (NR3A1) and/or ERβ.To date, two key conclusions can be drawn from the significant body of
work carried out on the specific roles of the two receptor subtypes in diverse estrogen target tissues. First,
ERα and ERβ have different biological functions, as indicated by their specific expression patterns and the
distinct phenotypes observed in ERα and ERβ knockout (αERKO and βERKO) mice. Second, ERα and ERβ
appear to have overlapping but also unique sets of downstream target genes, as judged from a set of microarray
experiments.Thus, ERα and ERβ have different transcriptional activities in certain ligand, cell-type, and
promoter contexts, which may help to explain some of the major differences in their tissue-specific biological
actions.The phenotypes observed for βERKO mice have suggested certain therapeutic areas to be further
explored.The development of ERβ-selective ligands active in animal disease models indicates new avenues
for clinical exploration. ERβ agonists are being explored and validated as drugs for a growing number of
indications. Hopefully, some ERβ targeted drugs will prove to be efficient in enhancing human health.
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Introduction
Estrogen is a key regulator of growth and differentiation
in a broad range of target tissues, including the
reproductive tract, mammary gland, and the central
nervous and skeletal systems [Couse and Korach, 1999;
Pettersson and Gustafsson, 2001]. Estrogen is also
known to be involved in many pathological processes
such as breast and endometrial cancer [Henderson et
al., 1988] and osteoporosis [Horowitz, 1993].The
presence of an estrogen binding receptor protein was
first reported in the early sixties by Elwood Jensen and
colleagues [Jensen and Jacobson, 1962].The cDNA
encoding an estrogen receptor (ER) protein was cloned
in the middle of the eighties [Green et al., 1986; Greene
et al., 1986] and this receptor was long believed to be the
only existing ER. However, in 1996, an additional ER was
cloned from rat prostate [Kuiper et al., 1996].This novel
receptor was designated ERβ and consequently the
originally cloned ER was renamed ERα. Orthologs of rat
ERβ were later cloned from many species including
human and mouse [Mosselman et al., 1996;Tremblay et
al., 1997]. ERα and ERβ belong to the superfamily of
nuclear receptors and specifically to the family of steroid
receptors that act as ligand-regulated transcription factors
[Beato, 1989; Evans, 1988]. Models of action involving
cooperation, as well as competition, between the two ER
proteins have been proposed [Matthews and Gustafsson,
2003].
Estrogenic therapy of today targets both ERα and ERβ.
Specific targeting of ERα or ERβ would open up novel
therapeutic opportunities, stratifying this hormonal
treatment, thereby reducing undesired side effects.
Examples of such unwanted effects include proliferation
of the uterus and mammary gland, most likely mediated
through ERα.The two receptor subtypes act in distinct
ways in several estrogen target cells and tissues
[Dahlman-Wright et al., 2006; Harris, 2007].Two major
conclusions may be drawn from this work. First, ERα and
ERβ have different biological functions, as indicated by
their distinct expression patterns and the different
phenotypes reported for the two ER isoform knockout
animals, respectively. Second, ERα and ERβ have
overlapping yet unique roles in estrogen signaling, as
judged from a number of gene expression profiling
studies.This article will review the current state of
knowledge of mechanisms of ERβ-mediated estrogen
signaling, the role of ERβ in physiology and disease and
potential diagnostic and pharmaceutical implications of
ERβ.
The ERβ gene and protein structure
The human ERβ gene (ESR2) is located on chromosome
14 q23.2, and is ∼61.2 kb.The ERβ protein is produced
from eight exons. Additionally, there are two untranslated
exons, 0N and 0K, in the 5′ region and an exon at the 3′
end that can be spliced to exon 7 to produce the
alternative ERβ isoform, ERβ2 [Kuiper et al., 1996; Kuiper
and Gustafsson, 1997] ( Figure 1). Human ERβ is a
protein of 530 amino acids [Ogawa et al., 1998a]. Both
the mouse and the rat ERβ genes contain open reading
frames that encode proteins of 549 amino acids [Leygue
et al., 1998]. A recent study of African, Caucasian and
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human ERβ548 exists [Xu et al., 2003].
ERβ is a member of the nuclear receptor superfamily and
shares common structural characteristics with the other
members of this family including five distinguishable
domains [Gronemeyer and Laudet, 1995].They are
named the A/B, C, D, E and F domains, respectively (
Figure 1).The N-terminal A/B domain is the most variable
region and the human ERα and ERβ share less than 20%
amino acid identity in this region, indicating that this
domain may contribute to ER subtype-specific actions on
target genes.This region harbors an activation function
(AF-1) [Tora et al., 1989] that is ligand-independent and
shows promoter- and cell-specific activity.The central
C-domain is the DNA-binding domain (DBD), which is
involved in specific DNA binding and receptor
dimerization.This domain is highly conserved between
ERα and ERβ and shares 95% amino acid identity.The
D-domain works as a flexible hinge between the DBD
and the ligand-binding domain (LBD), and is thus referred
to as the hinge domain.This domain, which is not well
conserved between ERα and ERβ (30%), appears to be
important for nuclear translocation and has been reported
to contain a nuclear localization signal [Picard et al.,
1990].The E-domain is referred to as the LBD and the
ERα and ERβ share approximately 55% amino acid
identity in this region.The LBD contains a
hormone-dependent activation function (AF-2) [Tora et
al., 1989] and is important for ligand binding and receptor
dimerization.The LBDs of ERα and ERβ have very similar
three-dimensional structures. However, the amino acids
lining the ligand-binding cavities of ERα and ERβ differ
in two positions [Brzozowski et al., 1997; Pike et al.,
1999]. Furthermore, the ligand-binding cavity of ERβ is
significantly smaller (∼20%) than that of ERα and this
may have implications for the selective affinity and
pharmacology of ligands [Brzozowski et al., 1997; Pike
et al., 1999].The F-domain has less than 20% amino acid
identity between the two ER subtypes and the functions
of this domain remain undefined.
ERβ promoters
The promoter organization of human ERβ has yet to be
clarified. Hirata et al. [Hirata et al., 2001] have analysed
the structure of the 5′-UTR of the ERβ mRNA in the
normal uterine endometrium and liver using 5′-rapid
amplification of the cDNA ends.This work has revealed
two isoforms of ERβ mRNA containing different
untranslated 5′-regions, which are generated by
alternative splicing of two upstream exons, exon 0K and
exon 0N ( Figure 1), to exon 1.These results indicate
that transcription of the human ERβ gene occurs from at
least two different promoters, named promoter 0N and
promoter 0K. Promoter 0N has been cloned and proven
to have promoter activity [Li et al., 2000]. Our laboratory
has cloned promoter 0K and our ongoing studies of
successive 5′ promoter deletions suggest that sequences
of promoter 0K between –534 and –1058 may contain
binding sites for key transcription factors driving basal
ERβ gene expression. Expression of the two transcripts
originating from promoters 0N and 0K, respectively, has
been detected in several human tissues, such as liver,
ejaculated spermatozoa, uterine endometrium and
myometrium [Hirata et al., 2001].We have shown that
transcripts from promoter 0N were more pronounced than
those from promoter 0K in normal breast epithelial cells
and a panel of breast cancer cell lines [Zhao et al., 2003].
It should be noted that full-length ERβ cDNA sequences
containing neither exon 0N nor exon 0K [Ogawa et al.,
1998a] have been reported, suggesting the presence of
(an) additional promoter(s). Further studies aimed at
characterization of promoters 0K and 0N and identification
and characterization of putative additional promoters
should aid in defining mechanisms for how expression of
the human ERβ gene is regulated.
The expression level of ERβ is also regulated through
chromatin condensation of promoter regions via
hypermethylation of CpG islands in the ERβ promoter.
Hypermethylation of the ERβ promoter is associated with
a marked decrease of ERβ mRNA expression in breast
cancer, prostate cancer as well as in cancer cell lines,
and the inhibition of DNA-methyltransferases reactivates
ERβ expression in these cell lines [Nojima et al., 2001;
Rody et al., 2005; Zhao et al., 2003; Zhu et al., 2004]. It
has been reported that hypermethylation of gene promoter
CpG islands plays a significant role in the development
and progression of various cancers [Dulaimi et al., 2004a;
Dulaimi et al., 2004b; Umetani et al., 2005].The
identification of hypermethylated genes in tumors has
become an accepted approach to assess tumor-related
gene inactivation [Herman and Baylin, 2003].The finding
of ERβ gene silencing via promoter hypermethylation in
tumors suggests an important role for the ERβ gene in
cancer progression and may be used as a prognostic
molecular biomarker. Interestingly, a significant increase
of ERβ promoter methylation was recently reported as
an epigenetic change in atherosclerosis and vascular
aging [Kim et al., 2007]. Moreover, methylation of a CpG
island at the ERβ promoter region was recently shown to
be a primary mechanism responsible for differential
expression of ERβ in endometriosis and endometrium
[Xue et al., 2007].
ERβ mRNA isoforms
Multiple ERβ isoforms exist as a result of either alternative
splicing of the last coding exons (exon 8 and exon 9,
respectively), deletion of one or more coding exons, or
alternative usage of untranslated exons in the 5′ region
[Lewandowski et al., 2002]. Among them, five full-length
transcripts, designated ERβ1-5, have been reported in
human ( Figure 1).The full-length human mRNA
translated from 8 exons, encoding 530 amino acids, is
named ERβ1.The full-length ERβ2-5 transcripts share
identical sequences with ERβ1 from exon 1 to exon 7,
but have unique sequences in place of exon 8 [Moore et
al., 1998].The predicted amino acid sequences of ERβ1-5
diverge at amino acid 469 within the LBD and extend to
the C-terminus. ERβ4 and ERβ5 isoforms were originally
identified as truncated transcripts containing only part of
the common exon 7 and different exon 8 sequences
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Review Estrogen receptor β updateFigure 1.  Structure of the human ERβ gene, protein and functional domains, and mRNA isoforms.  Gene: exons are indicated with boxes
and introns with lines.The numbers above each box indicate the size of the exons (bp); the numbers below each line designate the size of the respective
introns (bp). Dotted lines between gene and protein point to protein domain junctions. Protein: numbers indicate the total size of the protein in amino
acids. Isoforms: the shaded bar shows the divergent C-terminal regions among the isoforms.
[Moore et al., 1998]. A recent report confirmed their
existence as full-length transcripts [Poola et al., 2005].
Their functional aspects were subsequently examined by
Leung et al. [Leung et al., 2006]. In vitro studies show
that ERβ4 and β5 can heterodimerize with ERβ1 and
enhance its transactivation in a ligand-dependent manner.
The expression of ERβ3 appears to be restricted to the
testis [Moore et al., 1998] and functional studies on this
isoform have not been performed.
To date, there are data supporting protein expression of
several ERβ isoforms.The human variant ERβ2 (also
called ERβcx) encodes a protein of 495 amino acid
residues, with a molecular weight of 55.5 kDa. ERβ2 has
a unique C-terminus, due to alternative splicing, where
the amino acids corresponding to exon 8 are replaced
with 26 unique amino acids [Ogawa et al., 1998b].Thus,
ERβ2 lacks the AF-2 core region and has undetectable
affinity for estradiol and other tested ligands. Interestingly,
ERβ2 was shown to inhibit ligand-induced ERα
transcriptional activity on an ERE-reporter gene [Ogawa
et al., 1998b]. Our laboratory has further investigated the
possible molecular mechanism for the antagonistic effect
of ERβ2 on ERα-mediated transactivation. Our results
show that ERβ2 induces proteasome-dependent
degradation of ERα, presumably through the formation
of ERβ2/ERα heterodimers [Zhao et al., 2007].We
suggest that ERβ2-mediated degradation of ERα is at
least one mechanism whereby expression of ERβ2
inhibits recruitment of ERα to the estrogen-responsive
promoters, leading to suppression of ERα-regulated
genes.
Molecular mechanisms of estrogen
action
Estrogen action is exerted in target tissues via binding to
one of the two ERs, ERα or ERβ. Like other steroid
hormone receptors, ERs act as dimers to regulate
transcriptional activation. Full transcriptional activation
by ERs is mediated by synergism between two activation
domains, AF-1 at the N terminus and AF-2 in the LBD.
Both ERα and ERβ contain the potent AF-2 function, but
unlike ERα, ERβ seems to have a weaker corresponding
AF-1 function and thus depends more on the
ligand-dependent AF-2 for its transcriptional activation
function [Delaunay et al., 2000].
Evidence suggests that there are several distinct
pathways by which estrogens, via ERs, can regulate
biological processes [Hall et al., 2001]. In the classical
model of ER action, ligand-activated ERs bind specifically
to DNA at estrogen-responsive elements (EREs) through
their DNA binding domains and bring coregulators to the
transcription start site.The consensus ERE consists of
two half-sites (aGGTCAnnnTGACCt) separated by a
three-nucleotide spacer. However, many natural EREs
deviate substantially from the consensus sequences
[O'Lone et al., 2004]. Estrogen also modulates gene
expression by a second mechanism in which ERs interact
with other transcription factors, such as activating
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a process referred to as transcription factor cross talk
[Bjornstrom and Sjoberg, 2005; Kushner et al., 2000;
Saville et al., 2000]. An interesting difference between
ERα and ERβ is observed on AP-1 sites. In the presence
of estrogen, ERα induces AP-1-driven reporter activity,
whereas ERβ has no effect [Paech et al., 1997].
Raloxifene binding to ERβ induces transcriptional activity
through an AP-1 site, whereas binding to ERα results in
minimal activation examined under the same conditions
[Paech et al., 1997]. For ER:Sp1 complexes, that interact
with the GC-rich Sp1 motif [Batistuzzo de Medeiros et
al., 1997; Porter et al., 1997], alternative ligand responses
have been reported. In a study by Zou et al., ERβ
activated an RARα1 promoter-reporter construct
presumably by the formation of an ER:Sp1 complex [Zou
et al., 1999]. Antagonist binding to ERβ caused an
increase in reporter gene expression.This effect was
blocked by estrogen, which resembles the effect of ERβ
on an AP-1 site. Moreover, ERα and ERβ also exhibit
different transcriptional effects in regulation of the cyclin
D1 promoter [Liu et al., 2002]. ERα mediates the
stimulatory effect of estrogen on cyclin D1 expression,
whereas ERβ has a repressive effect. However, both ERα
and ERβ induce the expression of cyclin D1 in response
to antiestrogens.These effects were traced to a cAMP
response element (CRE) in the cyclin D1 promoter.
In addition, estrogen may elicit effects through
non-genomic mechanisms where estrogen has been
claimed to bind to ERs localized on the plasma membrane
of target cells [Nelson et al., 1986; Razandi et al., 1999;
Razandi et al., 2004]. It has been suggested that these
effects may be the result of estrogen activation of MAPK
and ERK signaling [Pedram et al., 2006] or release of
intracellular calcium [Mermelstein et al., 1996]. However,
such membrane-associated ER proteins have so far not
been conclusively identified and the mechanistic details
of activation through these non-genomic pathways remain
to be characterized. Recently, Galluzzo et al. [Galluzzo
et al., 2007] showed that ERβ palmitoylation is necessary
for receptor localization at the plasma membrane and for
the p38-dependent activation of downstream pro-apoptotic
cascade.
In addition to these ligand-induced transcriptional activities
of ERs, ligand-independent pathways to activate ERs
have been described. Growth factor signaling or
stimulation of other signaling pathways leads to activation
of kinases that can phosphorylate and thereby activate
ERs or associated coregulators in the absence of ligand
[Kato et al., 1995]. For example it has been shown that
the HER2 downstream signaling molecules ERK1 and
ERK2 can phosphorylate ER, leading to enhanced
sensitivity of the receptor to its cognate hormone and
additionally to ligand-independent receptor activation
[Martin et al., 2005].Tremblay et al. [Tremblay et al.,
1999] showed that phosphorylation of MAPK sites within
ERβ AF-1 stimulates ligand- and AF-2-independent
interaction with SRC-1 leading to transcriptional activation.
Furthermore, one recent microarray study revealed that
ERβ in the absence of ligand, stimulated and suppressed
the activity of a number of genes that were normally only
regulated by ERα in the presence of E2 [Chang et al.,
2006].
In summary, ERα and ERβ exert differential transcriptional
activities which, together with their distinct expression
patterns, may serve as a basis for the major differences
in their tissue-specific actions, the distinct phenotypes of
αERKO and βERKO animals and the specific
pharmacological effects exerted by ERα and ERβ
selective compounds.This complexity is further enhanced
by co-expression of splicing variants of ERs in the cells,
and the ability of ERs to form homodimers and
heterodimers.
Expression profiling reveals ERβ gene
expression programs
There have been a number of studies in the past few
years aimed at comprehensively unraveling the complete
estrogen-regulated gene expression programs in cancer
cells.These reports can be attributed to the introduction
of microarrays for global gene expression profiling.To
date, much of the work on identification of gene
expression profiles has been focused on the role of ERα
[Carroll and Brown, 2006; Lin et al., 2007a], but some
microarray studies have examined the role of ERβ in
regulating global gene expression programs. A summary
of studies on expression profiling of ERβ-regulated genes
is shown in Table 1.
Several gene expression studies have been performed
in breast cancer cell lines stably expressing ERβ [Chang
et al., 2006; Lin et al., 2007b; Omoto et al., 2003; Secreto
et al., 2007]. Chang et al. [Chang et al., 2006] conducted
microarray analyses to investigate gene regulatory effects
of ERβ in MCF7 cells. Of the genes modulated by ERβ,
the greatest numbers were associated with transcriptional
factors and signal transduction pathways. In particular,
ERβ regulated multiple components of TGFβ signaling,
consistent with the observations that TGFβ is normally
associated with the suppression of breast cancer cell
proliferation. Lin et al. [Lin et al., 2007b] identified a subset
of 14 DNA replication and cell cycle-related genes that
were specifically downregulated by ERβ in T47D cells.
However, assessment of the 5′ regulatory regions of the
four key downstream genes CDC2, CKS2, DNA2L and
CDC6 did not identify the consensus ERE.This raises
the possibility that either the expression of these genes
involves trans-elements such as other transcription factors
induced by ERβ or that ERβ is acting as a cofactor for
other transcription factors such as AP-1. Recently, data
obtained from microarray analyses of E2-stimulated
Hs578T cells stably expressing either ERα or ERβ
revealed that the patterns of E2-regulated gene
expression were largely unique to either ER subtype
[Secreto et al., 2007]. Gene expression profiles in aortas
from αERKO and βERKO mice revealed also that ERα-
and ERβ-dependent pathways regulate distinct sets of
genes [O'Lone et al., 2007].
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and the profiling platforms are listed.
Estrogens exert profound effects on bone, a tissue that
expresses ERα and ERβ.Thus, the second most
frequently used model system has been a human
osteoblast-like cell type, U2OS human osteosarcoma
cells [Kian Tee et al., 2004; Monroe et al., 2003; Monroe
et al., 2005; Stossi et al., 2004]. Because of the lack of
endogenous expression of either ERα or ERβ, U2OS
ERα or ERβ stably expressing cell lines provide a cell
model, permitting investigation of ER-subtype specific
actions on gene expression.These studies have
compared the gene-regulatory activities of ERα and ERβ
in U2OS cells and showed that ERα and ERβ share some
common target genes, although each receptor also
appears to have distinct sets of downstream target genes.
For example, genes encoding cystatin D, autotaxin or
stromal antigen 2 appear to be specifically regulated by
E2 via ERβ in bone [Stossi et al., 2004]. An interesting
finding was that E2 upregulated several genes associated
with cell motility selectively via ERβ, fitting with a model
of the selective E2 enhancement of the motility of
ERβ-containing cells.
Clearly, future studies should aim at investigating changes
in gene expression profiles in response to the modulation
of the activity of endogenous ERβ and at identifying the
first step in the signal cascade of ERβ, namely the global
binding of ERβ to DNA in the context of intact chromatin.
Roles of ERβ in human cancers
Targeted disruption of ERβ in mice has suggested roles
for ERβ in many tissues and organs, including the ovary,
uterus, mammary gland, brain, immune system and
ventral prostate [Harris, 2007].
Breast cancer
Estrogen is essential for growth and development of the
mammary glands, and has been associated with
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both ductal and lobular epithelial and stromal cells of the
rodent, whereas ERα is only found in the ductal and
lobular epithelial cells and not in stroma [Gotteland et al.,
1995]. ERβ expression in normal human breast and
breast cancer specimens and the relationship between
ERβ and other clinicopathological features and its role in
response to endocrine treatment has been extensively
investigated at both mRNA and protein levels. Consensus
regarding a protective role of ERβ against breast cancer
development seems to have been reached during the
recent few years. ERβ is lost in a majority of breast tumors
[Bardin et al., 2004a; Skliris et al., 2003], apparently by
ERβ promoter methylation in breast cancer cells [Rody
et al., 2005; Zhao et al., 2003]. Since promoter
methylation is frequently observed in cancer [Garinis et
al., 2002], these data suggest that ERβ is a possible
tumor suppressor gene. In vitro studies indicated that
ERβ is an important modulator of proliferation and
invasion of breast cancer cells, thus supporting the
hypothesis that the loss of ERβ expression could be one
of the events leading to breast cancer development
[Chang et al., 2006; Lazennec et al., 2001]. However,
this hypothesis needs to be confirmed, because it has
been shown that ERβ is expressed in the majority of
breast tumors, with immunohistochemical staining in
about 2/3 of breast tumors, similar to the percentage of
tumors which express ERα. Currently, only the ERα form
is measured for clinical decision-making and treatment
of breast cancer patients.
Prostate cancer
Estrogens can have profound effects on prostate growth
and differentiation as well as in the pathogenesis of
prostate cancer [Ho et al., 2006]. Since ERβ was originally
discovered in a rat prostate cDNA library, it was not
surprising that ERβ is highly expressed in both rat and
normal human prostate [Horvath et al., 2001; Kuiper et
al., 1996]. In the adult rodent ventral prostate, ERβ is
expressed in the epithelial cells, whereas ERα is
expressed in the stroma [Adams et al., 2002].The
estrogenic effects in the prostate may therefore be
exerted by both ERs, but in different cells. Our laboratory
has shown that ERβ knockout (βERKO) mice display
signs of prostatic hyperplasia with aging [Imamov et al.,
2004;Weihua et al., 2000].We also found that most
epithelial cells express the proliferation antigen Ki-67 and
the antiapoptotic factor BCLII in the prostates from
βERKO mice.We thus hypothesize that ERβ has an
antiproliferative and a prodifferentiative role in prostatic
epithelium.
Colon cancer
Colon cancer incidence and mortality rates are lower in
females compared with males, and numerous
epidemiological studies suggest that estrogen
replacement therapy (ERT) reduces the incidence of
colorectal cancer in postmenopausal women. ERβ is the
predominant ER in the colonic epithelium
[Campbell-Thompson et al., 2001; Konstantinopoulos et
al., 2003], suggesting that effects of estrogen in the colon
are mediated by ERβ. In colons from βERKO mice, the
number of proliferating cells was higher, and the migration
of labelled cells from base to lumen of the crypts was
faster when compared to wild-type mice [Wada-Hiraike
et al., 2006]. Additionally, immunohistochemical staining
revealed fewer apoptotic cells (cleaved caspase
3-positive), a significant decrease in expression of the
epithelial differentiation marker, cytokeratin CK20, the
adherens junction protein, α-catenin, and the
hemidesmosomal protein, plectin, in βERKO mice
[Wada-Hiraike et al., 2006].These findings suggest a role
for ERβ in the organization and architectural maintenance
of the colon.
Ovarian cancer
Ovarian cancer is a disease with high mortality, mainly
because of the lack of effective screening methods and
late symptoms. At the time of diagnosis, patients are often
at an advanced stage of the disease with occult
metastases within the peritoneal cavity.The role of
estrogens has been recently highlighted by the results of
three large prospective studies showing increased ovarian
cancer incidence and mortality in women who used
long-term estrogen replacement therapy [Anderson et
al., 2003; Lacey et al., 2002; Rodriguez et al., 2001]. A
loss of ERβ expression or a decrease in ERβ/ERα ratio
in epithelial ovarian cancer cells as compared with normal
tissues has been reported by several groups [Bardin et
al., 2004b; Brandenberger et al., 1998; Pujol et al., 1998;
Rutherford et al., 2000]. Recently, one study showed that
ERβ overexpression in ovarian cancer cells exerts
antitumoral effects [Bardin et al., 2004b;Treeck et al.,
2007]. Oral contraceptive (OC) use has been associated
with a decreased risk of ovarian cancer.The study by
Schildkraut et al. [Schildkraut et al., 2002] shows that the
combination OC formulations with high-progestin potency
appear to be associated with a greater reduction in
ovarian cancer risk than those with low-progestin potency.
Mechanisms underlying this reduction may include
inhibition of ovulation and/or some direct biological effects
of the progestin.
Validation of ERβ-selective agonists in
animal disease models
As described above, studies in knockout animals have
revealed a number of interesting phenotypes associated
with the lack of ERβ signaling and thus generated
hypotheses to be tested in animal disease models. Some
examples where these hypotheses have been validated
in animal models are outlined below.
Recently, ERβ-selective ligands have been characterized
in several clinically relevant animal models. In a study by
Walf and co-workers [Walf and Frye, 2005], vehicle,
17β-estradiol, or ER subtype selective agonists were
administered acutely to female ovariectomized rats prior
to behavioral testing. 17β-estradiol and the ERβ-selective
agonist diaryl-propionitrile (DPN) [Meyers et al., 2001],
but not the ERα-selective agonist propyl pyrazole triol
(PPT) [Stauffer et al., 2000], showed antidepressant-like
effects (reduced immobility) in the forced swim test, an
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Hegele-Hartung et al. [Hegele-Hartung et al., 2004], the
effects of ER subtype selective agonists on ovarian
biology were evaluated in hypophysectomized rats,
gonadotropin-releasing hormone antagonist-treated mice,
as well as intact rats.Their results showed that the ERβ
agonist caused stimulation of early folliculogenesis, a
decrease in follicular atresia, induction of ovarian gene
expression, and stimulation of late follicular growth,
accompanied by an increase in the number of ovulated
oocytes, similar to 17β-estradiol. In contrast, the ERα
agonist had little or no effect on these parameters,
implying that direct estrogen effects on ovarian follicular
development are mediated by ERβ.These results
suggested that ERβ agonists might be useful as a novel
therapeutic approach to improve ovarian function in sub-
or infertile women. Moreover, an ERβ-selective agonist,
ERB041, synthesized by Wyeth Research, has been
shown to be effective against inflammatory pain
[Leventhal et al., 2006].This compound has previously
been reported to be anti-inflammatory in animal models
[Harris et al., 2003]. Furthermore, an ERβ agonist
developed by Eli Lilly demonstrates involution of the
ventral prostate in rodent prostate models [Norman et al.,
2006]. More recently, studies performed with intact
aromatase knockout mice demonstrated that the
administration of an ERβ-specific agonist ablated
preexisting prostatic epithelial hyperplasia, whereas an
ERα-specific agonist did not [McPherson et al., 2007].
These findings suggested that ERβ-specific agonists
might be valid candidates for new pharmacological
approaches to manage dysregulated prostate growth.
Conclusions
Studies in βERKO mice together with high-throughput
gene expression profiling approaches have furthered our
understanding of the role of ERβ in physiology and
provided important glimpses into the molecular basis of
ERβ-mediated estrogen action in target cells. Future
studies should include validation of ERβ as a target for
candidate diseases and exploration of ERβ as a marker
for clinical decision-making and treatment. Hopefully, the
next decade will see a number of clinically useful
ERβ-agonists.
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